Prevention and management of concomitant infections in people living with HIV

Vincent is a medical specialist in sexual health and addiction. His research focuses on sexual health epidemiology, in order to develop more effective public health interventions to reduce transmission of HIV and other sexually transmissible infections.

https://www.unsw.edu.au/staff/vincent-cornelisse

 

Vincent is a medical specialist in sexual health and addiction. His research focuses on sexual health epidemiology, in order to develop more effective public health interventions to reduce transmission of HIV and other sexually transmissible infections.

https://www.unsw.edu.au/staff/vincent-cornelisse

 

Michael Peluso is an Assistant Professor of Medicine at the University of California, San Francisco, where he leads research programs focused on HIV infection and Long COVID.

Dr HM Sebitloane is an Obstetrician / gyanecologist with special interest in maternal/women's health and HIV. She is currently associate  professor  and academic head of dept at Nelson R Mandela School of Medicine, Univ of KwaZulu Natal< Durban South Africa. She has been an active member of ACTG / IMPAACT  clinical trials and served in the women"s health committee - WHISC (served 2 terms x 2 cycles),  FIGO ethics subcommittee (2 terms) as well as served in some of th WHO expert consultantion committees.

The WHO has drafted an ambitious goal of eradicating TB by 2030 and I want to be part of research agenda that achieves this. Rifampicin Resistant TB (RR TB), in all of its forms from rifampicin mono-resistant TB to Extensively Drug Resistant TB (XDR TB) is one of barriers to achieving this goal. There have been a number of breakthroughs in the treatment of these difficult to treat forms of TB. I have been involved some of the advances in this area including being involved bedaquiline trial and the subsequent incorporation of this drug into the South Africa National Program. I was the Principal investigator for the TB Alliance trial NIX that led to the registration by the FDA of BPaL for XDR TB. I am also the holder of USAID Grant BEAT Tuberculosis investigating a short all oral regimen for RR TB.

Vincent is a medical specialist in sexual health and addiction. His research focuses on sexual health epidemiology, in order to develop more effective public health interventions to reduce transmission of HIV and other sexually transmissible infections.

https://www.unsw.edu.au/staff/vincent-cornelisse

 

The WHO has drafted an ambitious goal of eradicating TB by 2030 and I want to be part of research agenda that achieves this. Rifampicin Resistant TB (RR TB), in all of its forms from rifampicin mono-resistant TB to Extensively Drug Resistant TB (XDR TB) is one of barriers to achieving this goal. There have been a number of breakthroughs in the treatment of these difficult to treat forms of TB. I have been involved some of the advances in this area including being involved bedaquiline trial and the subsequent incorporation of this drug into the South Africa National Program. I was the Principal investigator for the TB Alliance trial NIX that led to the registration by the FDA of BPaL for XDR TB. I am also the holder of USAID Grant BEAT Tuberculosis investigating a short all oral regimen for RR TB.

Dr HM Sebitloane is an Obstetrician / gyanecologist with special interest in maternal/women's health and HIV. She is currently associate  professor  and academic head of dept at Nelson R Mandela School of Medicine, Univ of KwaZulu Natal< Durban South Africa. She has been an active member of ACTG / IMPAACT  clinical trials and served in the women"s health committee - WHISC (served 2 terms x 2 cycles),  FIGO ethics subcommittee (2 terms) as well as served in some of th WHO expert consultantion committees.

Michael Peluso is an Assistant Professor of Medicine at the University of California, San Francisco, where he leads research programs focused on HIV infection and Long COVID.